Trials / Completed
CompletedNCT03592121
Study to Investigate the Effect of AB-101 in Breast Cancer Survivors
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Applied Biology, Inc. · Industry
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this research study is to investigate the possibility that a topical drug could restore nipple sensitivity and improve sexual quality of life in breast cancer survivors.
Detailed description
Approximately, 80% of breast cancer survivors undergoing will suffer from a permanent reduced reduction in nipple sensitivity and associated lowerdecrease in sexual quality of life. Currently, there are no treatments for restoring nipple sensitivity and the associatedto improve lower sexual quality of life this condition. It would thus be of great clinical benefit to post breast surgery patients if a provide a new safe and , effective , topical , on-demand, treatment for this condition can be developed.
Conditions
- Sexual Dysfunction
- Sexual Arousal Disorder
- Sexual Dysfunction, Physiological
- Breast Cancer
- Nipple Disorder
- Neuropathy
- Cancer of Breast
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AB-101 | Apply approximately 1 hour prior to sexual activity |
| DRUG | Placebo | Apply approximately 1 hour prior to sexual activity |
Timeline
- Start date
- 2018-07-09
- Primary completion
- 2019-10-12
- Completion
- 2019-10-12
- First posted
- 2018-07-19
- Last updated
- 2020-03-12
- Results posted
- 2020-03-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03592121. Inclusion in this directory is not an endorsement.